Skip to main content
⌘K
·
Launch Terminal
Launch Terminal
Home
SEC Filings
Home
SEC Filings
Filings
Filing Date
Form Type
Company
Description
AI
Link
Learn
MCP
API
Cookie Preferences
ASPE · Form 3 · Thompson Peter A. – Aspen Neuroscience, Inc. | Signal8
Material events
Financial results
Capital raises
Insider transactions
Fund filings
Any time
Sort
Advanced filters
Filings
Filing Date
Form Type
Company
Description
AI
Link
Browse AI-analysed SEC filings
Page 1 of 100 · 9,902 total
PBHC: 8-K · earnings release
PBHC · 8-K · 2026-11-02
BLMN: 8-K · material agreement
BLMN · 8-K · 2026-11-02
WCT: 6-K · reverse split
WCT · 6-K · 2026-11-02
WAVE: 6-K · other
WAVE · 6-K · 2026-11-02
KEP: 6-K · other
KEP · 6-K · 2026-11-02
PSO: 6-K · foreign private issuer
PSO · 6-K · 2026-11-02
ALX: 10-Q · periodic report
ALX · 10-Q · 2026-11-02
MSTR: 424B3 · prospectus supplement
MSTR · 424B3 · 2026-11-02
ORCL: 424B5 · prospectus supplement
ORCL · 424B5 · 2026-11-02
XMAX: 8-K · material agreement
XMAX · 8-K · 2026-11-02
FLNC: 8-K · leadership change
FLNC · 8-K · 2026-11-02
AKR: 8-K · earnings release
AKR · 8-K · 2026-11-02
MRVL: 8-K · acquisition merger
MRVL · 8-K · 2026-11-02
PSO: 6-K · other
PSO · 6-K · 2026-11-02
CHH: 8-K · earnings release
CHH · 8-K · 2026-11-02
MRVL: 8-K · acquisition merger
MRVL · 8-K · 2026-11-02
XERS: 8-K · leadership change
XERS · 8-K · 2026-11-02
ETI-P: 8-K · earnings release
ETI-P · 8-K · 2026-11-02
TGB: 6-K · other
TGB · 6-K · 2026-11-02
FOXA: 8-K · earnings release
FOXA · 8-K · 2026-11-02
VOD: 6-K · other
VOD · 6-K · 2026-11-02
GUER: 10-Q · periodic report
GUER · 10-Q · 2026-11-02
ENLV: 6-K · clinical trial
ENLV · 6-K · 2026-11-02
EL: 8-K · earnings release
EL · 8-K · 2026-11-02
SGC: 8-K · acquisition merger
SGC · 8-K · 2026-11-02
CRMT: 8-K · material agreement
CRMT · 8-K · 2026-11-02
NVMI: 6-K · other
NVMI · 6-K · 2026-11-02
ALLR: 8-K · material agreement
ALLR · 8-K · 2026-11-02
CODQL: 8-K · leadership change
CODQL · 8-K · 2026-11-02
GUER: 8-K · earnings release
GUER · 8-K · 2026-11-02
RECT: 6-K · acquisition merger
RECT · 6-K · 2026-11-02
WIMI: 6-K · delisting
WIMI · 6-K · 2026-11-02
IBATF: 8-K · earnings release
IBATF · 8-K · 2026-11-02
PKX: 6-K · earnings release
PKX · 6-K · 2026-11-02
RYAAY: 6-K · earnings release
RYAAY · 6-K · 2026-11-02
INTZ: 8-K · material agreement
INTZ · 8-K · 2026-11-02
PUK: 6-K · share repurchase
PUK · 6-K · 2026-11-02
VBIO: 8-K · leadership change
VBIO · 8-K · 2026-11-02
MAR: 10-Q · periodic report
MAR · 10-Q · 2026-11-02
CRMD: 8-K · earnings release
CRMD · 8-K · 2026-11-02
PHI: 6-K · auditor change
PHI · 6-K · 2026-11-02
L: 10-Q · periodic report
L · 10-Q · 2026-11-02
EVGO: SCHEDULE 13D/A · acquisition merger
EVGO · SCHEDULE 13D/A · 2026-11-02
LTBR: 8-K · earnings release
LTBR · 8-K · 2026-11-02
TSEM: 6-K · earnings release
TSEM · 6-K · 2026-11-02
BWAY: 6-K · material agreement
BWAY · 6-K · 2026-11-02
CIFR: 8-K · earnings release
CIFR · 8-K · 2026-11-02
TATT: 6-K · earnings release
TATT · 6-K · 2026-11-02
EMBJ: 6-K · material agreement
EMBJ · 6-K · 2026-11-02
LITE: 8-K · earnings release
LITE · 8-K · 2026-11-02
PRZO: 6-K · material agreement
PRZO · 6-K · 2026-11-02
KRYS: 8-K · earnings release
KRYS · 8-K · 2026-11-02
TATT: 6-K · earnings release
TATT · 6-K · 2026-11-02
AXSM: 8-K · earnings release
AXSM · 8-K · 2026-11-02
SHEL: 6-K · other
SHEL · 6-K · 2026-11-02
KRYS: 10-Q · periodic report
KRYS · 10-Q · 2026-11-02
TRIP: 8-K · asset sale
TRIP · 8-K · 2026-11-02
DEO: 6-K · foreign private issuer
DEO · 6-K · 2026-11-02
TEM: 10-Q · periodic report
TEM · 10-Q · 2026-11-02
RDHL: 6-K · clinical trial
RDHL · 6-K · 2026-11-02
CANF: 6-K · other
CANF · 6-K · 2026-11-02
TATT: 6-K · earnings release
TATT · 6-K · 2026-11-02
MAR: 8-K · earnings release
MAR · 8-K · 2026-11-02
III: 8-K · earnings release
III · 8-K · 2026-11-02
TEM: 8-K · earnings release
TEM · 8-K · 2026-11-02
KMDA: 6-K · earnings release
KMDA · 6-K · 2026-11-02
TLSA: 6-K · clinical trial
TLSA · 6-K · 2026-11-02
PINE: 8-K · acquisition merger
PINE · 8-K · 2026-11-02
OMI: 8-K · material agreement
OMI · 8-K · 2026-11-02
XPEV: 6-K · other
XPEV · 6-K · 2026-11-02
BCS: 6-K · share repurchase
BCS · 6-K · 2026-11-02
KOS: 8-K · debt financing
KOS · 8-K · 2026-11-02
PERI: 6-K · acquisition merger
PERI · 6-K · 2026-11-02
BORR: 6-K · other
BORR · 6-K · 2026-11-02
KOS: 8-K · earnings release
KOS · 8-K · 2026-11-02
GFI: 6-K · regulatory action
GFI · 6-K · 2026-11-02
MFGCF: 6-K · regulatory action
MFGCF · 6-K · 2026-11-02
IDXX: 8-K · earnings release
IDXX · 8-K · 2026-11-02
MKDW: 6-K · offering registration
MKDW · 6-K · 2026-11-02
LAZ: 8-K · acquisition merger
LAZ · 8-K · 2026-11-02
CNA: 10-Q · periodic report
CNA · 10-Q · 2026-11-02
HLN: 6-K · share repurchase
HLN · 6-K · 2026-11-02
URG: 8-K · leadership change
URG · 8-K · 2026-11-02
NCTY: 6-K · proxy statement
NCTY · 6-K · 2026-11-02
RITE: 10-Q · periodic report
RITE · 10-Q · 2026-11-02
PENG: SCHEDULE 13D/A · ownership disclosure
PENG · SCHEDULE 13D/A · 2026-11-02
ECX: 6-K · material agreement
ECX · 6-K · 2026-11-02
NTES: 6-K · share repurchase
NTES · 6-K · 2026-11-02
LI: 6-K · other
LI · 6-K · 2026-11-02
CNA: 8-K · earnings release
CNA · 8-K · 2026-11-02
BEKE: 6-K · share repurchase
BEKE · 6-K · 2026-11-02
RGBP: 8-K · debt financing
RGBP · 8-K · 2026-11-02
EMBJ: 6-K · proxy statement
EMBJ · 6-K · 2026-10-30
EMBJ: 6-K · proxy statement
EMBJ · 6-K · 2026-10-30
GBLI: 8-K · leadership change
GBLI · 8-K · 2026-10-30
SPWR: S-1 · offering registration
SPWR · S-1 · 2026-10-30
TD: 6-K · debt financing
TD · 6-K · 2026-10-30
FTAI: 10-Q · periodic report
FTAI · 10-Q · 2026-11-02
EMBJ: 6-K · acquisition merger
EMBJ · 6-K · 2026-10-30
GPRK: 6-K · acquisition merger
GPRK · 6-K · 2026-11-02
1
2
3
4
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Next ›
